INS and type 2 diabetes mellitus: All groups with HbA1c >7% saw a significant change ranging from 0.2% ± 0.8% with initial HbA1c values 7.0%–7.9% to 2.3% ± 1.0% for those with baseline Hba1c >9.0% (P < 0.001), while those with HbA1c <7% maintained this level of glycemic control.26 In conclusion, there is mounting evidence that rtCGM can improve glycemic control in insulin-treated patients with T2D, in addition to other benefits.